Lundbeck and its partners at Otsuka are embarking on a lengthy Phase III journey in search of solid evidence that their Alzheimer's drug Lu AE58054 in combination with donepezil can improve the swiftly eroding cognitive functions of Alzheimer's patients.
Regulators at the FDA stamped an approval on Brintellix, a new therapy to treat major depression from Lundbeck and Takeda, just hours before the government prepared to hunker down in a partial shutdown.
Danish drugmaker Lundbeck has been hiring more than 200 sales reps in the U.S. in anticipation of the FDA approval of the blockbuster antidepressant Brintellix. Well, now they have something to sell.
Supply-chain simplification and new procurement processes are also part of the plan.
The pharma company expects to save about a half billion Danish kroner annually in the move.
Steps taken by Danish drugmaker Lundbeck to keep U.S. states from using one of its drugs to execute prisoners are working, sort of. States are running out of unexpired supplies of Lundbeck's pentobarbital but are turning to alternatives, not halting executions.
Lundbeck is fired up and ready for its launch of the potential blockbuster antidepressant Brintellix. Though still awaiting regulatory approval, the Danish drugmaker is recruiting more than 200 sales reps to prepare for take-off, Bloomberg reports.
Lundbeck and Otsuka are quickly ramping up a 3,000-patient Phase III study for an experimental Alzheimer's drug after claiming success in improving cognition among a group of patients taking the treatment alongside donepezil for 24 weeks in a Phase II trial.
Lundbeck may be adding to the pharma layoff toll with another restructuring plan. After announcing plans to cut 600 jobs and revamp its European operations last year, the company now says it's aiming to "optimize" and "simplify" its commercial structure with an overhaul that could cost 50 to 55 more positions.
Regulators in both the U.S. and the U.K. have been cracking down on pay-for-delay deals in recent months, with the issue going before the U.S. Supreme Court in March. Now, it seems, EU regulators will join them. The EU's anti-trust regulator, is set to fine 9 generic drugmakers for accepting money to keep their low-cost products off the market.